4Moving Biotech welcomes Luc Boblet as Chief Executive Officer to lead next phase of growth
02 Julio 2024 - 12:30AM
Business Wire
4Moving Biotech (4MB), a clinical-stage subsidiary of 4P-Pharma
specializing in immuno-inflammation and osteoarthritis, is pleased
to announce the appointment of Luc Boblet as Chief Executive
Officer. The company, having successfully completed its Phase I
clinical trial and a preparatory in silico Phase 2 analysis, looks
to Luc Boblet's seasoned expertise in biotech entrepreneurship and
strategic development to guide the forthcoming stages of clinical
proof of concept and early market access.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240701233556/en/
Luc Boblet, CEO OF 4Moving Biotech
(Photo: Business Wire)
Luc Boblet, a biotech entrepreneur with two decades of
experience, joins 4MB following his tenure at Egle Therapeutics,
where his leadership was essential in advancing novel
immunotherapies and securing a robust Series A funding backed by a
big pharma strategic alliance. His previous roles included founding
and leading companies such as H-IMMUNE - acquired by HiFiBIO - and
Pathoquest, where he excelled in driving innovation, closing
fundraising and forging strategic partnerships as instrumental
catalyst of growth.
"Luc's appointment comes at a turning point for 4Moving Biotech
as we have concluded a milestone Phase I trial for our leading drug
candidate and are advancing strategic discussions with the FDA,
toward potential accelerated approval" said Revital
Rattenbach, founder and CEO of 4P-Pharma
and co-founder of 4Moving. "His track record in steering
biotech ventures and his strategic approach to partnerships will be
invaluable as we advance our clinical programs and explore
opportunities for pharma co-development and partnership."
As CEO of 4Moving Biotech, Luc Boblet's immediate focus will be
on overseeing the design and implementation of the development
strategy for the upcoming Phase II clinical trials, as well as
cultivating partnerships that align with the company's vision for
growth and patient access to innovative treatments.
Luc Boblet, CEO of 4Moving
Biotech said: "The opportunity to lead 4Moving Biotech at
this juncture is one that is aligned with my commitment to bringing
pioneering therapies for untreated severe diseases. The company's
progress in drug development and the potential to significantly
improve patient outcomes in osteoarthritis is a strong foundation
for future success. I am looking forward to applying my experience
in corporate strategy business development to deliver our value
proposal and establish meaningful partnerships."
About 4Moving Biotech
4Moving Biotech, a subsidiary of 4P-Pharma, is dedicated to
developing advanced first in class therapies in the field of
immuno-inflammation and osteoarthritis. With a commitment to
improving patient care, 4MB is actively engaged in the clinical
development of novel treatments poised to enhance quality of life
for patients worldwide.
Biography of Luc Boblet, CEO of 4Moving Biotech.
Luc Boblet is a serial biotech entrepreneur with 20 years of
experience in entrepreneurship, business development, corporate
finance and early drug development. Luc is coming from Egle
Therapeutics, spin out of Institut Curie dedicated to developing
novel Regulatory T-cells based immunotherapies for oncology and
autoimmune diseases, he has co-founded in early 2020. As a founding
CEO, he built Egle Tx with a vision to become a game changer in the
field of Tregs immunomodulation catalyzed by strategic alliance
with Takeda Pharmaceutical and backed by 45M€ Series A from a
high-quality syndicate of renowned international investors. Before
creating Egle Tx, Luc co-founded and ran H-IMMUNE, start-up spun
out of French Nuclear Agency (CEA), developing novel
anti-check-point immunotherapies against T-effector and Tregs for
oncology. He paved H-IMMUNE corporate path through partnerships
with Pierre Fabre Laboratories and Norther Biologics and have
exited H-IMMUNE through an acquisition by HiFiBIO in 2018. Before
co-founding H-IMMUNE, Luc co-founded and ran Pathoquest, a start-up
company spun out of Institute Pasteur, which develops disruptive
unbiased NGS-based diagnostics in the field of infectious diseases.
Under his guidance, Pathoquest raised two VC-backed rounds of
financing, closed strategic collaborations and corporate
partnerships with leading pharma companies (CERBA Laboratories and
Covance), and launched several clinicals trials in France and the
U.S. From 2011 to 2015, he served on the board of directors of the
BioAster Technological Research Institute. He started his career in
technology transfer, consulting in finance and business development
for toxicogenomics R&D. Luc Boblet holds a biotech engineering
degree, master’s degree in Virology and has been trained as a PhD
in Virology from University Paris VII.
About 4Moving Biotech
Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving
Biotech is a clinical stage biotechnology company dedicated to the
development of the Disease-Modifying Osteoarthritis Drug (DMOAD).
Its mission is to provide a sustainable therapeutic solution to the
significant unmet medical need of osteoarthritis. The company is
headquartered at the Pasteur Institute in Lille, France.
Website: https://www.4movingbiotech.com/ LinkedIn:
https://fr.linkedin.com/company/4moving-biotech X:
https://twitter.com/4Moving_Biotech
The only version of the 4Moving Biotech press release that is
legally binding is the one in its original language. Translations
must always be compared to the source text, which will establish
precedence. The press release text resulting from a translation
should not be considered official in any way.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701233556/en/
Press: Emmanuel Dadje Communication Manager -
emmanuel.dadje@4P-Pharma.com +33 6 30 06 12 13